Comparison of the Changes in Plasma Human Growth Hormone (HGH) and Immuno-Reactive Glucagon (IRG) after Intravenous and Subcutaneous Injection of Glucagon

Sugase, Takahito; Nonaka, Kyohei; Yoshida, Takashi; Morishita, S; Toyoshima, Hiroyuki; Tanaka, Ryoichi; Tarui, Seiichiro; Shima, Kenji

doi:10.1507/endocrj1954.23.187

Cited by 7 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypoglycaemia symptoms occur 90±120 min after glucagon administration. 9 The percentage of cases with hypoglycaemia-related symptoms was higher in the glucagon-treated group than in the butyl scopolamine bromide-treated group. This study clearly demonstrates that administration of glucose tablets 1 h after endoscopy signi®cantly reduces the frequency of hypoglycaemia-related symptoms.…”

Section: Discussionmentioning

confidence: 85%

“…Reactive hypoglycaemia may be a serious event in patients premedicated with glucagon, because glucagon stimulates insulin release. Hypoglycaemia symptoms occur 90–120 min after glucagon administration 9 . The percentage of cases with hypoglycaemia‐related symptoms was higher in the glucagon‐treated group than in the butyl scopolamine bromide‐treated group.…”

Section: Discussionmentioning

confidence: 96%

“…Glucagon has fewer adverse affects on the cardiovascular system 7 , 8 than anticholinergic drugs, but the efficacy and safety of glucagon for endoscopic premedication in elderly patients have not been fully evaluated. Hypoglycaemia, caused by the response to glucagon‐induced hyperglycaemia, has been reported to occur about 90–120 min after glucagon administration 9 . The frequency and prevention of such reactive hypoglycaemia when glucagon is used for endoscopic premedication have not been investigated.…”

Section: Introductionmentioning

confidence: 99%

“…Hypoglycaemia, caused by the response to glucagon-induced hyperglycaemia, has been reported to occur about 90±120 min after glucagon administration. 9 The frequency and prevention of such reactive hypoglycaemia when glucagon is used for endoscopic premedication have not been investigated. The aim of this prospective, multicentre study was to clarify the safety and ef®cacy of glucagon as a premedication for upper gastrointestinal endoscopy compared with an anticholinergic drug.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide

Hashimoto¹,

Adachi²,

Ishimura³

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Glucagon inhibits digestive motility and is used for endoscopic premedication; however, its effect on cardiopulmonary function during endoscopy has not yet been fully investigated. Aim: To clarify the efficacy and safety of glucagon compared with butyl scopolamine bromide as upper gastrointestinal endoscopy premedication. Methods: Two hundred and forty consecutive patients over 40 years of age, referred for upper gastrointestinal endoscopy, without any complications, were studied. These patients were randomly premedicated with butyl scopolamine bromide (SC group) or glucagon (G group). Time course changes in blood pressure, arterial oxygen saturation, heart rate and the number of retching episodes during endoscopy were examined. The efficacy of glucose tablets after upper gastrointestinal endoscopy to prevent hypoglycaemia caused by glucagon was evaluated. Cardiopulmonary parameters were also examined in 77 complicated patients with glucagon premedication (GC group). Results: A continuous increase in heart rate during upper gastrointestinal endoscopy was observed in the SC group, but not in the G and GC groups. Blood pressure, arterial oxygen saturation and number of retching episodes were not different between the groups. Hypoglycaemia‐related symptoms were frequent in the G group without glucose tablets, but were prevented by the administration of glucose. Conclusions: Glucagon has a weaker effect on cardiopulmonary function during upper gastrointestinal endoscopy than butyl scopolamine bromide. Glucose administration prevents hypoglycaemia‐related symptoms caused by glucagon.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide

Hashimoto¹,

Adachi²,

Ishimura³

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…There were no significant changes in heart rate, blood pressure and electrocardiogram during and after the test. The response to glucagon was also examined in four patients and ten healthy subjects as described previously (Sugase et al, 1976).…”

Section: Methodsmentioning

confidence: 99%

EXAGGERATED INSULIN SECRETORY RESPONSE IN PATIENTS WITH INSULINOMAS TO MIDAGLIZOLE, A DRUG WITH α₂‐ADRENERGIC BLOCKING ACTIVITY

Yamada

Kôno

Hanafusa

et al. 1988

Clinical Endocrinology

View full text Add to dashboard Cite

Midaglizole is a new alpha 2-adrenergic blocking agent which increases insulin release from normal pancreatic islets. We studied its effect in four patients with insulinomas. In three patients oral administration of 150 mg of midaglizole caused a large increase in serum insulin and a corresponding decrease in plasma glucose. The magnitude of the response cannot exclude the possibility that midaglizole has direct beta cell stimulatory activity. Two of the three patients had operations, and their insulin responses to midaglizole became normal after removing the tumours. In contrast, midaglizole did not stimulate insulin secretion in the fourth patient. A midaglizole stimulation test might be useful in screening patients with insulinomas.

show abstract

Increased muscle sympathetic nerve activity after glucagon administration in man

Takayama

Nakajima

Toma

et al. 1995

Journal of the Autonomic Nervous System

View full text Add to dashboard Cite

Comparison of the Changes in Plasma Human Growth Hormone (HGH) and Immuno-Reactive Glucagon (IRG) after Intravenous and Subcutaneous Injection of Glucagon

Cited by 7 publications

References 13 publications

Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide

Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide

EXAGGERATED INSULIN SECRETORY RESPONSE IN PATIENTS WITH INSULINOMAS TO MIDAGLIZOLE, A DRUG WITH α₂‐ADRENERGIC BLOCKING ACTIVITY

Increased muscle sympathetic nerve activity after glucagon administration in man

Contact Info

Product

Resources

About

Comparison of the Changes in Plasma Human Growth Hormone (HGH) and Immuno-Reactive Glucagon (IRG) after Intravenous and Subcutaneous Injection of Glucagon

Cited by 7 publications

References 13 publications

Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide

Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy—a comparative study with butyl scopolamine bromide

EXAGGERATED INSULIN SECRETORY RESPONSE IN PATIENTS WITH INSULINOMAS TO MIDAGLIZOLE, A DRUG WITH α2‐ADRENERGIC BLOCKING ACTIVITY

Increased muscle sympathetic nerve activity after glucagon administration in man

Contact Info

Product

Resources

About

EXAGGERATED INSULIN SECRETORY RESPONSE IN PATIENTS WITH INSULINOMAS TO MIDAGLIZOLE, A DRUG WITH α₂‐ADRENERGIC BLOCKING ACTIVITY